Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -58.37M | -2.29M | -4.11M | -45.12M | 22.50M |
| Total Depreciation and Amortization | 25.75M | 26.13M | 25.02M | 24.81M | 21.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.60M | 20.93M | 50.31M | 7.85M | 3.19M |
| Change in Net Operating Assets | -2.79M | 21.75M | -51.36M | -49.20M | 11.49M |
| Cash from Operations | -4.81M | 66.52M | 19.86M | -61.66M | 58.54M |
| Capital Expenditure | -568.00K | -- | -427.00K | -129.00K | -455.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00 | -293.09M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.66M | -19.22M | -50.88M | 341.93M | -30.15M |
| Cash from Investing | 7.09M | -19.22M | -51.31M | 48.71M | -30.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.12M | 13.67M | 8.56M | 23.74M | 3.28M |
| Repurchase of Common Stock | -88.00K | -4.56M | -31.00K | -811.00K | -46.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.24M | -- | 0.00 | -1.86M | -2.30M |
| Cash from Financing | -7.20M | 9.12M | 8.53M | 21.07M | 935.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.92M | 56.42M | -22.92M | 8.11M | 28.86M |